Market Overview

Discovery Labs Announces FDA Approval of SURFAXIN for Prevention of Respiratory Distress Syndrome

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome in premature infants at high risk for RDS. SURFAXIN is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine. Discovery Labs anticipates that SURFAXIN will be commercially available in the United States in late 2012.

Posted-In: News FDA

 

Most Popular

Related Articles (DSCO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free